| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Lecanemab (Mouse IGG2a) targets soluble beta-amyloid (Abeta) peptides, a key player in the pathogenesis of Alzheimer's disease. As a monoclonal antibody, it binds to Abeta oligomers and protofibrils, promoting their clearance from the brain. This reduces Abeta deposition and neurotoxicity, leading to cognitive protection. The murine IGG2a constant region allows for in vivo studies in mouse models without generating an anti-drug antibody response against the human Fc region.
|
|---|---|
| ln Vitro |
Lecanemab (Mouse IGG2a) almost abolishes Abeta accumulation in astrocytes and rescues neurons from Abeta-induced cell death in vitro. This demonstrates potent neuroprotective activity by reducing the toxic effects of Abeta on neuronal cells. The antibody likely binds to soluble Abeta aggregates, preventing their interaction with neurons and facilitating their uptake and degradation by glial cells.
|
| ln Vivo |
Lecanemab (Mouse IGG2a) is used in vivo in mouse models of Alzheimer's disease. In a transgenic mouse model (e.g., APP/PS1 or 5xFAD mice), administration of the antibody reduces Abeta plaque burden in the brain, lowers levels of soluble Abeta oligomers, and improves cognitive function in behavioral tests (e.g., Morris water maze). It has the potential to reduce cognitive decline, consistent with the therapeutic effects of the humanized version of Lecanemab.
|
| Enzyme Assay |
The binding affinity of Lecanemab (Mouse IGG2a) for soluble beta-amyloid can be assessed using surface plasmon resonance (SPR). Procedure: Recombinant human beta-amyloid (Abeta42) is immobilized on a CM5 sensor chip. Varying concentrations of Lecanemab (Mouse IGG2a) (e.g., 0.1-100 nM) are injected over the chip surface in running buffer (PBS, 0.05% Tween-20, pH 7.4). Association and dissociation rates are recorded, and the equilibrium dissociation constant (KD) is calculated using a 1:1 binding model. Alternatively, ELISA can be performed using immobilized Abeta42 peptide and anti-mouse IgG-HRP for detection.
|
| Cell Assay |
The neuroprotective activity can be assessed in primary neuronal cultures. Procedure: Primary rat cortical neurons are isolated from embryonic day 18 rats and cultured for 10-14 days. Neurons are exposed to pre-formed Abeta42 oligomers (5 uM) in the presence or absence of Lecanemab (Mouse IGG2a) (0.1-10 ug/mL) for 24-48 hours. Cell viability is measured by MTT or LDH release assays. Apoptosis is assessed by caspase-3/7 activity. Alternatively, co-cultures of astrocytes and neurons can be used to measure Abeta accumulation in astrocytes by immunofluorescence staining.
|
| Animal Protocol |
The in vivo efficacy of Lecanemab (Mouse IGG2a) can be evaluated in a transgenic mouse model of Alzheimer's disease (e.g., 5xFAD or APP/PS1 mice). Procedure: Female 5xFAD mice (6-8 months old) with established Abeta pathology are randomized into groups (n=10-12). Lecanemab (Mouse IGG2a) is administered intraperitoneally at doses of 5, 10, and 30 mg/kg twice weekly for 3 months. Control mice receive PBS or isotype control antibody. Cognitive function is assessed using the Morris water maze and novel object recognition tests. At study endpoint, brains are harvested for Abeta plaque quantification by immunohistochemistry (6E10 antibody), soluble Abeta levels by ELISA, and microglial activation by Iba-1 staining.
|
| ADME/Pharmacokinetics |
A specific pharmacokinetic profile for Lecanemab (Mouse IGG2a) is not provided. As a monoclonal antibody (molecular weight ~150 kDa), it will have typical antibody PK properties: slow clearance (half-life of 5-10 days in mice), low volume of distribution (limited to vascular and interstitial spaces), and negligible oral bioavailability (requiring intravenous or intraperitoneal administration). The murine IGG2a isotype may have a shorter half-life than humanized antibodies due to potential murine-specific Fc receptor interactions.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Lecanemab (Mouse IGG2a) is not provided. As an antibody targeting beta-amyloid, potential toxicities include amyloid-related imaging abnormalities (ARIA) such as brain edema (ARIA-E) and cerebral microhemorrhage (ARIA-H), which have been observed with humanized Lecanemab in clinical trials. The research-grade murine version is not intended for human use. Standard laboratory safety for antibody handling applies.
|
| References | |
| Additional Infomation |
Lecanemab (Mouse IGG2a) is a research-grade monoclonal antibody whose variable region is identical to that of the FDA-approved Alzheimer's drug Lecanemab (Leqembi®). The constant region is of mouse IGG2a isotype, making it suitable for in vivo studies in mouse models without interference from anti-human antibody responses. It targets soluble beta-amyloid aggregates and has been shown to rescue neurons from Abeta-induced cell death and reduce Abeta accumulation in astrocytes. This product is for research use only and is not intended for human therapeutic use.
|
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
